The new alternative treatment in which growth factor rich plasma injections facilitate the restoration of ovarian function. RENOVO 2 is a novel technology that has meant significant clinical progress in the medical field and is starting to be used as an alternative for treating cases of POI and diminished ovarian reserve. Patients who has responded to the treatment saw an increase in the number of oocytes obtained. The selection criteria for Poor Ovarian Responders include: · Patient whose AMH level was very low which was less than 0.5 to 1.2 ng/ml; · Patients with a history of poor ovarian response having less than three eggs per cycle even after good stimulation with Gonadotrophins and patients with low estradiol levels; · Antral Follicle Count of less than five from both ovaries; · Patients with high FSH and LH levels , and who were in the menopausal stage; · Lacking any other under lying disease causing female infertility;